Company news, research breakthroughs, and major announcements across industries.

Home/Health

Health |Johnson & Johnson

Johnson & Johnson reports VARIPULSE and OMNYPULSE results for atrial fibrillation

Johnson & Johnson
Johnson & Johnson

Johnson & Johnson reported first real-world VARIPULSE Pro data, including 100% acute procedural success, and 12-month OMNYPULSE results in which 82.5% of patients stayed free of documented atrial arrhythmia.

  • PublishedOctober 22, 2026
  • IndustryHealth
  • LanguageEN

Published by Jnj. Read the original announcement for the full release.

Read the full announcement →

Latest from leading organizations

Explore recent announcements by organization